Form 4: Eli Lilly Executive Johna Norton Reports Stock Transactions

Executive Vice President of Global Quality at Eli Lilly, Johna Norton, reported the acquisition and disposal of company stock and restricted stock units on February 1, 2024.

Summary

• Johna Norton, an Executive Vice President at Eli Lilly, reported transactions involving company stock and restricted stock units.
• On February 1, 2024, Norton acquired 1,268 shares of common stock through the vesting of restricted stock units.
• Also on February 1, 2024, 566 shares were disposed of at a price of $645.61 per share.
• Following these transactions, Norton directly owns 30,816 shares of common stock.
• Norton also has indirect ownership of 402 shares through a 401(k), 1,769 shares through a partner's 401(k), and 128 shares through a partner.

Sentiment

Score: 5

Explanation: The document reflects routine executive stock transactions, which are neither particularly positive nor negative. The sentiment is neutral.

Positives

• The vesting of restricted stock units indicates a positive incentive structure for company executives.
• The acquisition of shares through vesting increases the executive's stake in the company.

Negatives

• The disposal of 566 shares could be interpreted as a slight reduction in the executive's direct holdings.

Risks

• Executive stock transactions can sometimes be interpreted as a signal of the executive's sentiment about the company's future performance, although this is not always the case.
• Large sales of stock by executives could potentially put downward pressure on the stock price.

Industry Context

Executive stock transactions are a normal part of corporate governance and compensation practices in the pharmaceutical industry. These transactions are routinely disclosed to the SEC.

Comparison to Industry Standards

• Executive stock transactions are common across the pharmaceutical industry, with companies like Pfizer (PFE), Johnson & Johnson (JNJ), and Merck (MRK) also reporting similar filings.
• The vesting of restricted stock units is a standard practice for executive compensation, aligning executive interests with shareholder value.
• The reported price of $645.61 per share is consistent with the current trading price of Eli Lilly stock.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they reflect routine executive compensation and stock ownership changes.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Eli Lilly, LLY, stock transaction, insider trading, Form 4, restricted stock units, executive compensation, Johna Norton